Glenmark Pharma acquires Abbreviated New Drug Applications from Wockhardt

28 Jun 2022 , 10:32 AM

Glenmark Pharmaceuticals Ltd, an innovation-driven, global pharmaceutical company on Tuesday has announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc., USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) in the United States from Wockhardt Limited.

Sanjeev Krishan, President of Glenmark Pharmaceuticals Inc., USA, commented “The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world.

Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines.”

Glenmark’s current portfolio consists of 175 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company informed.

At around 10:31 AM, Glenmark Pharmaceuticals was trading at Rs382.80 per share down by Rs3.65 or 0.94% on the BSE.